
News|Articles|November 18, 2026
SNO 2026 Shows Lasting Responses, Ongoing Research for Safusidenib
Author(s)Cancer Network Staff
Fact checked by: Tim Cortese, Russ Conroy
Safusidenib showed durable responses in IDH1-mutant glioma, and ongoing trials will test the agent in oligodendroglioma, after vorasidenib, and as maintenance.
Advertisement
Advertisement
At the 2026 Society for Neuro-Oncology (SNO) Annual Meeting, investigators presented 4 posters on safusidenib, an investigational oral inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) with high potency, selectivity, and blood-brain barrier permeability.1-4 One reported updated phase 2 efficacy and safety data in chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma. The other 3 described ongoing studies in grade 3 oligodendroglioma, glioma that progressed on vorasidenib (Voranigo), and astrocytoma with high-risk features.
Related to this article

Adding trotabresib to chemoradiotherapy did not improve progression-free or overall survival and was associated with more dose reductions and interruptions.

In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.

Ajai Chari, MD, discussed sequencing CAR T and bispecifics, fixed-duration therapy, emerging targets, and academic partnership in multiple myeloma.

At the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.

The FDA has assigned a target action date of June 28, 2027, for selinexor plus ruxolitinib as a therapeutic regimen for patients with myelofibrosis.

In the pivotal phase 3 REGAL trial, galinpepimut-S was generally well tolerated among patients with acute myeloid leukemia.

Amir T. Fathi, MD, discusses where venetoclax/azacitidine fits in fit patients with AML and why a phase 3 trial may be unlikely.
Advertisement
Advertisement

